Literature DB >> 23616668

The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains.

Ndongala M Lubaki1, Philipp Ilinykh, Colette Pietzsch, Bersabeh Tigabu, Alexander N Freiberg, Richard A Koup, Alexander Bukreyev.   

Abstract

Ebola virus (EBOV) infections are characterized by deficient T lymphocyte responses, T lymphocyte apoptosis, and lymphopenia in the absence of direct infection of T lymphocytes. In contrast, dendritic cells (DC) are infected but fail to mature appropriately, thereby impairing the T cell response. We investigated the contributions of EBOV proteins in modulating DC maturation by generating recombinant viruses expressing enhanced green fluorescent protein and carrying mutations affecting several potentially immunomodulating domains. They included envelope glycoprotein (GP) domains, as well as innate response antagonist domains (IRADs) previously identified in the VP24 and VP35 proteins. GP expressed by an unrelated vector, but not the wild-type EBOV, was found to strongly induce DC maturation, and infections with recombinant EBOV carrying mutations disabling GP functional domains did not restore DC maturation. In contrast, each of the viruses carrying mutations disabling any IRAD in VP35 induced a dramatic upregulation of DC maturation markers. This was dependent on infection, but not interaction with GP. Disabling of IRADs also resulted in up to a several hundredfold increase in secretion of cytokines and chemokines. Furthermore, these mutations induced formation of homotypic DC clusters, which represent close correlates of their maturation and presumably facilitate transfer of antigen from migratory DC to lymph node DC. Thus, an individual IRAD is insufficient to suppress DC maturation; rather, the suppression of DC maturation and the "immune paralysis" observed during EBOV infections results from a cooperative effect of two or more individual IRADs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23616668      PMCID: PMC3700277          DOI: 10.1128/JVI.03316-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  79 in total

1.  Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells.

Authors:  Brian P Dolan; Kenneth D Gibbs; Suzanne Ostrand-Rosenberg
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

2.  Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication.

Authors:  Amy L Hartman; Jason E Dover; Jonathan S Towner; Stuart T Nichol
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses.

Authors:  Kavitha Yaddanapudi; Gustavo Palacios; Jonathan S Towner; Ivy Chen; Carlos A Sariol; Stuart T Nichol; W Ian Lipkin
Journal:  FASEB J       Date:  2006-10-05       Impact factor: 5.191

4.  Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling.

Authors:  Washington B Cárdenas; Yueh-Ming Loo; Michael Gale; Amy L Hartman; Christopher R Kimberlin; Luis Martínez-Sobrido; Erica Ollmann Saphire; Christopher F Basler
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity.

Authors:  Carisa A Zampieri; Jean-Francois Fortin; Garry P Nolan; Gary J Nabel
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

6.  Ebola virus infection of human PBMCs causes massive death of macrophages, CD4 and CD8 T cell sub-populations in vitro.

Authors:  Manisha Gupta; Christina Spiropoulou; Pierre E Rollin
Journal:  Virology       Date:  2007-03-27       Impact factor: 3.616

7.  Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.

Authors:  Kelly L Warfield; Dana L Swenson; Gene G Olinger; Warren V Kalina; M Javad Aman; Sina Bavari
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

8.  A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge.

Authors:  Alexander Bukreyev; Lijuan Yang; Sherif R Zaki; Wun-Ju Shieh; Pierre E Rollin; Brian R Murphy; Peter L Collins; Anthony Sanchez
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

9.  Successful topical respiratory tract immunization of primates against Ebola virus.

Authors:  Alexander Bukreyev; Pierre E Rollin; Mallory K Tate; Lijuan Yang; Sherif R Zaki; Wun-Ju Shieh; Brian R Murphy; Peter L Collins; Anthony Sanchez
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

10.  Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs.

Authors:  Nancy J Sullivan; Thomas W Geisbert; Joan B Geisbert; Devon J Shedlock; Ling Xu; Laurie Lamoreaux; Jerome H H V Custers; Paul M Popernack; Zhi-Yong Yang; Maria G Pau; Mario Roederer; Richard A Koup; Jaap Goudsmit; Peter B Jahrling; Gary J Nabel
Journal:  PLoS Med       Date:  2006-05-16       Impact factor: 11.069

View more
  54 in total

1.  Mechanism of human antibody-mediated neutralization of Marburg virus.

Authors:  Andrew I Flyak; Philipp A Ilinykh; Charles D Murin; Tania Garron; Xiaoli Shen; Marnie L Fusco; Takao Hashiguchi; Zachary A Bornholdt; James C Slaughter; Gopal Sapparapu; Curtis Klages; Thomas G Ksiazek; Andrew B Ward; Erica Ollmann Saphire; Alexander Bukreyev; James E Crowe
Journal:  Cell       Date:  2015-02-26       Impact factor: 41.582

2.  Ebola Virus Produces Discrete Small Noncoding RNAs Independently of the Host MicroRNA Pathway Which Lack RNA Interference Activity in Bat and Human Cells.

Authors:  Abhishek N Prasad; Adam J Ronk; Steven G Widen; Thomas G Wood; Christopher F Basler; Alexander Bukreyev
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

3.  Different Temporal Effects of Ebola Virus VP35 and VP24 Proteins on Global Gene Expression in Human Dendritic Cells.

Authors:  Philipp A Ilinykh; Ndongala M Lubaki; Steven G Widen; Lynnsey A Renn; Terence C Theisen; Ronald L Rabin; Thomas G Wood; Alexander Bukreyev
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

4.  Ebolavirus Chimerization for the Development of a Mouse Model for Screening of Bundibugyo-Specific Antibodies.

Authors:  Philipp A Ilinykh; Jessica Graber; Natalia A Kuzmina; Kai Huang; Thomas G Ksiazek; James E Crowe; Alexander Bukreyev
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

5.  Global phosphoproteomic analysis of Ebola virions reveals a novel role for VP35 phosphorylation-dependent regulation of genome transcription.

Authors:  Andrey Ivanov; Palaniappan Ramanathan; Christian Parry; Philipp A Ilinykh; Xionghao Lin; Michael Petukhov; Yuri Obukhov; Tatiana Ammosova; Gaya K Amarasinghe; Alexander Bukreyev; Sergei Nekhai
Journal:  Cell Mol Life Sci       Date:  2019-09-28       Impact factor: 9.261

6.  Impact of Měnglà Virus Proteins on Human and Bat Innate Immune Pathways.

Authors:  Caroline G Williams; Joyce Sweeney Gibbons; Timothy R Keiffer; Priya Luthra; Megan R Edwards; Christopher F Basler
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

7.  Role of Transmembrane Protein 16F in the Incorporation of Phosphatidylserine Into Budding Ebola Virus Virions.

Authors:  Patrick Younan; Mathieu Iampietro; Rodrigo I Santos; Palaniappan Ramanathan; Vsevolod L Popov; Alexander Bukreyev
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

8.  Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes.

Authors:  Andrea Rivera; Ilhem Messaoudi
Journal:  ACS Infect Dis       Date:  2015-03-30       Impact factor: 5.084

9.  Disruption of Phosphatidylserine Synthesis or Trafficking Reduces Infectivity of Ebola Virus.

Authors:  Patrick Younan; Mathieu Iampietro; Rodrigo I Santos; Palaniappan Ramanathan; Vsevolod L Popov; Alexander Bukreyev
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

Review 10.  Development and application of reporter-expressing mononegaviruses: current challenges and perspectives.

Authors:  Darryl Falzarano; Allison Groseth; Thomas Hoenen
Journal:  Antiviral Res       Date:  2014-01-23       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.